Stock TERN TERNS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Terns Pharmaceuticals, Inc.

Equities

TERN

US8808811074

Biotechnology & Medical Research

Real-time Estimate Cboe BZX
Other stock markets
 09:23:22 03/05/2024 pm IST 		5-day change 1st Jan Change
5.415 USD +2.36% Intraday chart for Terns Pharmaceuticals, Inc. +9.98% -16.80%
29/04 Terns Pharmaceuticals, Inc. Announces Data from Ongoing Phase 1 Pharmacokinetic Study of Allosteric BCR-ABL Inhibitor Tern-701 in Adult Healthy Volunteers and Highlights Potential for Competitive Differentiation CI
10/04 Terns Pharmaceuticals, Inc. Appoints Melita Sun Jung as Chief Business Officer CI

Business Summary

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Its pipeline includes three clinical-stage development programs: TERN-701, TERN-601 and TERN-501. TERN-701 is its oral, potent, allosteric BCR-ABL tyrosine kinase inhibitors (TKI) specifically targeting the ABL myristoyl pocket for CML, a form of cancer that begins in the bone marrow and leads to the growth of leukemic cells. TERN-601 is a small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist that is intended to be orally administered for obesity and other metabolic diseases. TERN-501 is a thyroid hormone receptor beta (THR-b) agonist with high metabolic stability and liver distribution. It is also focused on developing the TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity.

Number of employees: 66

Managers

Managers TitleAgeSince
Amy Burroughs CEO
 Chief Executive Officer 53 07/02
Erin Quirk PSD
 President 53 01/19/01
Mark Vignola DFI
 Director of Finance/CFO 46 11/20/11
Bryan Yoon COO
 Chief Operating Officer 47 01/20/01
Jeffrey R. Jasper CTO
 Chief Tech/Sci/R&D Officer - 06/22/06
Justin Ng IRC
 Investor Relations Contact - -
Emil T. Kuriakose PRN
 Corporate Officer/Principal 44 01/23/01
Melita Sun Jung PRN
 Corporate Officer/Principal 46 22/04

Members of the board

Members of the board TitleAgeSince
David Fellows CHM
 Chairman 67 01/20/01
Jeffrey Kindler BRD
 Director/Board Member 68 01/20/01
Carl Gordon BRD
 Director/Board Member 59 01/18/01
Hong Bo Lu BRD
 Director/Board Member 53 01/20/01
Radhika Tripuraneni BRD
 Director/Board Member 44 26/22/26
Jill Quigley BRD
 Director/Board Member 48 01/20/01
Amy Burroughs CEO
 Chief Executive Officer 53 07/02
Erin Quirk PSD
 President 53 01/19/01
Ann Taylor BRD
 Director/Board Member - 28/21/28

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 64,674,780 62,397,905 ( 96.48 %) 0 96.48 %

Shareholders

NameEquities%Valuation
OrbiMed Advisors Private Equity
11.78 %
7,619,135 11.78 % 50 M $
Vivo Capital LLC
9.648 %
6,237,329 9.648 % 41 M $
Deep Track Capital LP
9.435 %
6,100,000 9.435 % 40 M $
Suvretta Capital Management LLC
9.029 %
5,837,126 9.029 % 38 M $
Venrock Associates
6.956 %
4,497,117 6.956 % 30 M $
Point72 Asset Management LP
6.065 %
3,921,226 6.065 % 26 M $
Millennium Management LLC
5.382 %
3,479,630 5.382 % 23 M $
BlackRock Advisors LLC
4.955 %
3,203,236 4.955 % 21 M $
Fidelity Management & Research Co. LLC
4.625 %
2,990,402 4.625 % 20 M $
LAV Management Co., Ltd.
4.488 %
2,901,566 4.488 % 19 M $

Company contact information

Terns Pharmaceuticals, Inc.

1065 East Hillsdale Boulevard Suite 100

94404, Foster City

+650 525 5535

http://www.ternspharma.com
address Terns Pharmaceuticals, Inc.(TERN)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
5.29 USD
Average target price
14.21 USD
Spread / Average Target
+168.70%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
TERNS PHARMACEUTICALS, INC. Stock Terns Pharmaceuticals, Inc.
-16.80% 342M
MODERNA, INC. Stock Moderna, Inc.
+24.32% 48.09B
LONZA GROUP AG Stock Lonza Group AG
+46.90% 40.62B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-2.44% 40.43B
CELLTRION, INC. Stock Celltrion, Inc.
-6.95% 28.36B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+7.48% 24.89B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-20.17% 19.01B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.13% 12.09B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-0.29% 11.88B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-0.32% 11.8B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. TERN Stock
  4. Company Terns Pharmaceuticals, Inc.